{"nctId":"NCT00395993","briefTitle":"Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding","startDateStruct":{"date":"2005-05"},"conditions":["Anemia"],"count":456,"armGroups":[{"label":"Ferric Carboxymaltose (FCM)","type":"EXPERIMENTAL","interventionNames":["Drug: Ferric Carboxymaltose (FCM)"]},{"label":"Ferrous Sulfate tablets","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ferrous Sulfate tablets"]}],"interventions":[{"name":"Ferric Carboxymaltose (FCM)","otherNames":[]},{"name":"Ferrous Sulfate tablets","otherNames":["Oral Iron Tablets"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female subjects \\>/= 18 years of age\n* History of Heavy uterine bleeding\n* Hgb \\</= 11\n* Practicing acceptable birth control\n* Demonstrate ability to understand and comply with protocol\n\nExclusion Criteria:\n\n* Known Hypersensitivity to oral or IV iron\n* Anemia other than iron deficiency anemia\n* Iron storage disorders\n* Initiation of treatment that may effect degree of heavy uterine bleeding\n* Anticipated need for surgery\n* Severe psychiatric disorder\n* Active infection\n* Positive Pregnancy test\n* Known Hep B or C or Active Hepatitis\n* Received investigational Drug within 30 days\n* Alcohol or drug abuse","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Achieving 'Clinical Success'. Clinical Success is Defined as an Increase in Hemoglobin of â‰¥ 2.0 g/dL","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":null},{"groupId":"OG001","value":"139","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":230},"commonTop":["Headache","Nausea","Constipation","Blood phosphorus decreased","Diarrhea"]}}}